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Abstract 
Electrospinning has emerged as a widely accepted 
technique with ability to produce nanofibers that can be 
employed in many biomedical applications. In particular, drug-
eluting nanofibers have become very popular in controlled 
release of small molecule drugs.  In this study, nanofibers from 
blends of polylactocaprone (PCL) and chitosan (CHI) were 
electrospun with the ability to load a model drug, 
acetylsalicylic acid (ASA), at 10 wt%. PCL/CHI fibers 
exhibited smooth surface morphology at polymer compositions 
ranging from 100/0 to 40/60 with or without the incorporation 
of ASA. Mechanical properties suggested a brittle failure 
mechanism for fibers loaded with drug. In vitro drug release 
study displayed a controlled release profile of ASA up to 48 h. 
Our study aims to explore the drug-polymer interactions and 
their effects on fiber structure, mechanical properties and drug 
release profile. 
1. Introduction 
In the field of drug release, there are many different 
routes to administer drugs for cells/tissues uptake. Among 
them, electrospun nanofibers have shown several advantages 
for topical administration on mucosal sites. These advantages 
include the ability to achieve high drug loading (up to 60%) 
and encapsulation efficiency (up to 100%), to incorporate 
various polymers for accommodations of a wide variety of 
biological agents, to modulate release, and to provide process 
simplicity and cost-effectiveness [1]. 
Electrospinning is a process that continuously draws 
nanofibers through an electric field. A typical setup of 
electrospinning consists of a syringe with a needle tip attached 
to it, a syringe pump, a stationary plate collector, and a voltage 
source (Figure 1). During the electrospinning process, polymer 
solution is pumped through the needle tip of the syringe at a 
constant flow rate. The voltage source creates a surface charge 
density that, for successful electrospinning to occur, must 
overcome the surface tension of the polymer solution to 
produce fibers. The negative portion of the voltage source is 
connected to the plate collector at a certain distance from the 
needle tip, resulting an electric field between the needle tip and 
collector. This electric field forces fibers to travel and deposit 
on the plate collector through rapid solvent evaporation, and 
thus creating a fiber mat [2]. 
Nanofibers created through electrospinning have been 
used for many applications such as defense, environmental 
engineering, and healthcare [3]. Electrospun nanofibers have 
also been used in the field of controlled drug release. With the 
numbers of biocompatible polymers that are available for 
electrospinning, fibers produced from electrospinning have 
become very popular in the field of drug release. In this study, 
polymer solutions of polycaprolactone (PCL) and chitosan 
(CHI) at various blend ratios were electrospun into fibers. Both 
PCL and CHI are biodegradable and biocompatible [4], 
whereas PCL is a hydrophobic synthetic polymer and CHI is a 
hydrophilic natural polymer. We hypothesize that drug release 
from PCL/CHI fibers is modulated through 
hydrophilic/hydrophobic components from polymer matrix. In 
addition, drug-polymer interactions attribute to effects in 
mechanical properties and drug release profiles [5]. As a result, 
we aim to study both effects to provide scientific 
understanding on small molecule drug release from electrospun 
nanofibers and to further inform the development of drug-
eluting nanofibers for controlled release purpose. 
 
2. Materials and Methods 
2.1 Materials 
Chitosan powder (90% deacetylation) was obtained from 
Xi’an Zhongyun Biotechnology Co., Ltd. (China). 
Polycaprolactone (Mw = 80KDa) was obtained from Huaian 
Ruanke Co., Ltd. (China). Glacial acetic acid (AA), 
hexafluoro-2-propanol (HFIP), and phosphate-buffered saline 
(PBS) were obtained from VWR Analytical. Acetylsalicylic 
acid (ASA) (99% purity) was obtained from Alfa Aesar. All 
the other chemicals were of reagent grade and used as received 
without further purification. 
2.2 Preparation of Electrospun PCL/CHI fibers 
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15 wt% of PCL was dissolved in HFIP and 4 wt% of CHI 
was dissolved in 90% AA/DI water (v/v) mixture. The 
solutions were combined to create blend solutions at ratios 
100/0, 80/20, 60/40, and 40/60 PCL/CHI. ASA was added to 
blend solutions at 10 wt% (w/w = wt%). All solutions were 
allowed to mix overnight before electrospinning. 
Electrospinning was carried out using a 2 mL syringe with a 25 
G blunt-end needle, 20 μL/min flow rate, 14-17 kV of 
voltages, and a distance of 7 to 9 cm from the tip of the needle 
to the stationary collector plate. 
2.3 SEM Imaging and Material Characteristics 
Fiber morphologies and fiber diameters were analyzed by 
using a JOEL scanning electron microscopy. Circular punches 
were taken from the fiber mats and sputter coated with Au/Pd 
for 30 s using a sputter-coater. SEM micrographs were 
acquired at 5 kV, using a spot size 3, and a working distance of 
15.0 cm. Fiber diameters were measured using an image 
analysis tool (ImageJ) (n = 70). 
Fiber uniformity measurements were performed by a 
thickness gage (resolution = 0.01 mm). A 15 x 15 cm square 
paper with 10 mm grids was used to determine the location for 
thickness collection. 
2.4 Mechanical Testing 
Mechanical testing was performed on an Instron 3342 
equipped with a 100 N load cell. Dog-bone samples (ASTM 
standard D1708-96) were created using a stainless steel die 
(ODC Tooling and Molds, Waterloo ON, Canada). Samples 
were then mechanically stretched under 21°C and 55% RH (n 
= 3). Tensile tests were performed at a strain rate of 0.01 s
−1
 
where load and displacement data were obtained. Young ׳s 
modulus (linear region before 2% strain) and tensile strength 
(zero slope) were calculated from each corresponding stress–
strain curve. 
2.5 In Vitro Drug Release Study 
½" diameter disks were cut from the fiber mats using a 
metal die. The mass for each sample was taken and theoretical 
drug loading was calculated. Disk samples were then placed in 
glass vials containing 10 mL of PBS as the release media and 
incubated at 37°C using an orbital shaker at 100 rpm 
(ThermoFisher). 200 μL of the liquid samples were then taken 
at time intervals of 1, 4, 8, 24, and 48 h. 
HPLC analysis was used to quantify ASA concentration 
in the release media. A Waters UV-HPLC system equipped 
with a C18 column was used to quantify drug levels in 
samples. The HPLC mobile phase consisted of a 50% HPLC 
graded H2O and 50% acetonitrile. The HPLC methods 
included 25 °C column temperature, 1 mL/min flow rate, 5 min 
run time, 10 μL sample injection volume and UV/vis detection 
at 270 nm and 295 nm for acetylsalicylic acid and salicylic 
acid, respectively. An ASA standard curve was developed by 
series dilution at concentrations of 200, 100, 50, 10, and 0.1 
μg/mL. 
 
3. Results and Discussion 
3.1 Fiber Structure and Uniformity   
PCL/CHI nanofibers were produced at CHI concentration 
up to 60% in the fiber. Both blank and drug-loaded fibers 
(PCL/CHI = 60/40) exhibited a smooth and defect-free surface 
with no morphological changes (Figure 2). Average fiber 
diameters (PCL/CHI = 60/40) were 293 ± 44 μm and 258 ± 46 
μm for blank and drug-loaded fibers, respectively. Average 
fiber diameter was slightly lower for the drug-loaded fibers 
perhaps due to the addition of the ASA increasing the 
spinnability of the fibers. Uniformity measurements on blank 
fiber mat (PCL/CHI = 100/0) revealed that fibers were mostly 
deposited at the center of the collection plate and gradually 
leveled off toward outer area (Figure 3). 
3.2 Mechanical Testing 
Representative engineering stress and engineering strain 
curves of blank and drug-loaded fibers (PCL/CHI = 100/0 and 
40/60) showed an initial elastic region followed by failure at 
tensile strength (Figure 4A and 4B). Interestingly, blank fibers 
at all compositions exhibited significantly higher ductility then 
the drug-loaded fibers. In contrast, drug-loaded fibers 
displayed a dependence of stiffness and tensile strength on 
composition of chitosan in the fibers, suggesting a strong drug-
polymer interaction. Our finding is in accordance with 
previous work [6]. 
Quantitative analysis on the mechanical properties 
showed that average Young's modulus and tensile strength of 
the drug-loaded fibers at PCL/CHI = 80/20 and 60/40 were 
significantly higher than those of the blank fibers (p > 0.05) 
(Figure 5A and 5B). The average Young’s moduli of drug 
loaded fibers were 17.6 ± 4.9, 43.1 ± 2.4, 41.1 ± 27.8, and 38.6 
± 18.4 MPa for PCL/CHI blends of 100/0, 80/20, 60/40, and 
40/60, respectively. These values were much higher than the 
Young’s moduli of the blank fibers at 12.4 ± 1.4, 17.1 ± 1.6, 
13.3 ± 9.3, and 27.3 ± 6.2 MPa of the corresponding PCL/CHI 
compositions. Similarly, tensile strength of the drug-loaded 
fibers were 1.2 ± 0.5, 2.5 ± 0.4, 2.1 ± 0.2, and 0.6 ± 0.1 MPa 
when increasing chitosan composition in the fibers, which 
were higher than the corresponding blank fibers of 2.2 ± 0.2, 
1.8 ± 0.7, 1.7 ± 1.4, and 0.9 ± 0.5 MPa. The differences in these 
values indicate that there is a strong drug-polymer interaction 
resulting in the change of mechanical properties.  
3.2 Drug Release 
As mentioned previously, electrospun nanofibers have the 
ability to provide a controlled release mechanism due to 
hydrophobicity/hydrophilicity of the polymer matrix and 
loading of the drug [7]. In particular, hydrophilic small 
molecule drugs loaded in PCL typically shows a burst release 
within 24 h [6]. As a result, we explore the release profiles of 
ASA from various compositions of PCL/CHI fibers (Figure 6). 
As shown in the graph, the release profile of ASA showed a 
sustained release behavior from pure PCL fibers over 2 days 
while increasing chitosan composition increased the release 
rate of ASA. Cumulative ASA released from PCL/CHI (100/0) 
fibers exhibited a steady increase from 4 h to 48 h, showing a 
zero-order release kinetic, suggesting that the current fiber 
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platform can be used for controlled release of hydrophilic 
small molecule drugs.  
 
4. Summary 
This study aims to investigate the ability to electrospin 
PCL/CHI fibers and the ability to load a hydrophilic drug 
(ASA) at high loading (10 wt%). In addition, characterizations 
of the fibers showed a strong drug-polymer interaction in 
PCL/CHI fibers. We found correlations between fiber 
diameters and the presence of ASA with a significant change 
in mechanical properties. Our results showed that the 
incorporation of drug in the fibers modified the mechanical 
properties of these fibers. We were able to demonstrate the 
ability to sustain the release of ASA from the fibers. This study 
contributes to the scientific understanding of drug-polymer 
interactions on mechanical properties and controlled release of 
hydrophilic small molecule drugs.  
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Figure 1. Schematics of an 
electrospinning process. 
 
Figure 2. Scanning electron microscopic images of PCL/CHI 
(60/40) (A) blank and (b) drug-loaded fibers. Scale bar = 5μm. 
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Figure 3. Thickness of fiber mat using to inform fiber 
uniformity after electrospinning (PCL/CHI = 100/0). 
 
Figure 4.  (A) Representative of engineering stress-strain curves of blank and drug-loaded 
PCL/CHI (100/0) fibers. (B) Representative of engineering stress-strain curves of blank 
and drug-loaded PCL/CHI (40/60) fibers. 
 
Figure 5. (A) Average elastic modulus of blank and drug-loaded fibers at various 
PCL/CHI compositions. (B) Average tensile strength of blank and drug-loaded fibers 
at various PCL/CHI compositions. 
 
Figure 6. In vitro drug release studies using various PCL/CHI fibers showing (A) 
standard ASA curve and (B) cumulative ASA released from PCL/CHI fibers. 
 
